Our mission is to transform the clinical management of patients with cancer by developing and delivering innovative molecular imaging technologies to address unmet clinical needs, and reliably inform diagnosis and treatment decisions.
Our team is made up of industry leaders and experts in the field of radiopharmaceutical development and commercialisation.
Blue Earth Diagnostics is backed by Syncona Limited, a leading FTSE250 healthcare company focused on investing in and building global leaders in life science.
Find out how this technique works
Find out about prostate cancer
Cellular mechanisms for amino acid transport
Our research focus
Who we are
Who we work with
See how you can join the team
Where we are going to be
® (fluciclovine (18F)) in France.Oxford, UK – December 12, 2018 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that the first commercial production of Axumin® (fluciclovine (18F)) in France...
Read More ›– sNDA seeks to expand Axumin® (fluciclovine F 18) label for use in detection and continuing assessment in adults with glioma – BURLINGTON, Mass. and OXFORD, UK – December...
Read More ›– Presented at 23rd Annual Scientific Meeting of the Society for Neuro-Oncology – BURLINGTON, Mass. and OXFORD, UK – Nov. 19, 2018 – Blue Earth Diagnostics, a molecular imaging...
Read More ›BURLINGTON, Mass. and OXFORD, UK, November 14, 2018 – Blue Earth Diagnostics, a molecular imaging diagnostics company, today announced that a presentation related to the clinical use of 18F-fluciclovine...
Read More ›